CNAT Conatus Pharmaceuticals Inc.

7.58
+0  (6%)
Previous Close 7.16
Open 7.17
Price To book 8.59
Market Cap 198.36M
Shares 26,169,000
Volume 762,768
Short Ratio 3.53
Av. Daily Volume 590,731

SEC filingsSee all SEC filings

  1. 8-K - Current report 17704265
  2. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17694528
  3. 8-K - Current report 17691292
  4. 8-K - Current report 17621370
  5. 8-K - Current report 17617922

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment commenced - March 15, 2017.
JZP-258
Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
Phase 2b trial to be initiated 2Q 2017.
Emricasan
NASH cirrhosis - ENCORE-LF trial
Phase 2b initiated November 2016. Data due 2018.
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2 topline data released Jan 2015
Emricasan
Acute-on-Chronic Liver Failure (ACLF)
Phase 2 data released September 2015.
Emricasan
Portal Hypertension
Phase 2b initiated May 2014. Topline data due 1H 2018.
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2 trial initiated January 2016. Data are due 2018.
Emricasan
NASH fibrosis - ENCORE-NF trial
Phase 2 topline data released early January 2016
Emricasan
Liver Cirrhosis

Latest News

  1. Conatus Posters at EASL Meeting Address MELD Score Dynamics and Outcomes in Decompensated Liver Cirrhosis Patients, Including NASH Patients, Awaiting Liver Transplantation
  2. Are Options Traders Betting on a Big Move in Conatus Pharmaceuticals (CNAT) Stock?
  3. Conatus Pharmaceuticals and MannKind Look Forward to Promoting Their Brand
  4. Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst'
  5. Conatus to Present at Upcoming Investor Conferences
  6. Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4
  7. Conatus reports 4Q loss
  8. Conatus Pharmaceuticals Reports 2016 Financial Results and Program Updates
  9. Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results
  10. Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store?
  11. Conatus Pharmaceuticals Appoints William R. LaRue as Independent Board Member
  12. Conatus to Present at BIO CEO & Investor Conference
  13. Conatus Pharmaceuticals Promotes Daniel L. Ripley to Senior Vice President, Business Development, Program and Alliance Management
  14. Short Interest In Conatus Pharmaceuticals Surges
  15. Henry Schein Hurt by Higher Costs, Lacks Growth Drivers
  16. Walgreens Teams Up with Fedex to Boost Retail Performance
  17. NuVasive at 52-Week High on Preliminary Results, MHLW Nod
  18. Can The Uptrend Continue for Conatus (CNAT)?
  19. Align Poised On Global Expansion & Invisalign Teen Growth
  20. Five December Deals That Fueled Big Biotech Run-Ups On Wall Street